{"id":41370,"date":"2024-02-14T09:10:35","date_gmt":"2024-02-14T15:10:35","guid":{"rendered":"https:\/\/leukemiarf.org\/?p=41370"},"modified":"2024-05-02T10:03:30","modified_gmt":"2024-05-02T15:03:30","slug":"blinatumomab-b-cell-acute-lymphoblastic-leukemia","status":"publish","type":"post","link":"https:\/\/leukemiarf.org\/news\/blinatumomab-b-cell-acute-lymphoblastic-leukemia\/","title":{"rendered":"Blina may be effective in first-line treatment of Pediatric B-ALL"},"content":{"rendered":"\n
Blinatumomab, or Blina, appears to be a safe and effective first-line treatment option for young patients with B-cell acute lymphoblastic leukemia (B-ALL) who don\u2019t tolerate chemotherapy, according to a study recently published in the Journal of Clinical Oncology<\/a><\/strong><\/em>.<\/p>\n\n\n\n Chemotherapy treatments can have a negative impact on a child\u2019s quality of life. This study looked at the possibility that Blina could be a less toxic first step in treatment for some patients.<\/p>\n\n\n\n From February 2018 to February 2023, 105 patients were followed.<\/p>\n\n\n\n After analysis, researchers concluded that Blina is safe and effective in first-line treatment of chemotherapy-intolerant children and young persons with ALL.<\/p>\n\n\n\n